News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|April 21, 2025

Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

Author(s)Nihar Desai, MD, MPH, Nathan Wong, PhD, Jeremy Wigginton, MD, MBA, FAAFP

Experts discuss whether providers should wait for another complete scientific statement from the National Lipid Association (NLA) or new guidelines from organizations like the American Heart Association (AHA) before implementing the 2024 NLA recommendation for universal lipoprotein(a) (Lp[a]) measurement.

Episodes in this series

EP. 1 Lp(a) in ASCVD and Guideline Recommendations

EP. 1 Lp(a) in ASCVD and Guideline Recommendations

EP. 2 Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP. 2 Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP. 3 The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP. 3 The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP. 4 Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP. 4 Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP. 5 Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP. 5 Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP. 6 How the Genetic Nature of Lp(a) Levels Influences Screening

EP. 6 How the Genetic Nature of Lp(a) Levels Influences Screening

EP. 7 A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP. 7 A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP. 8 The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP. 8 The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP. 9 Evidence Supporting 2024 Guidance for Lp(a) Testing

EP. 9 Evidence Supporting 2024 Guidance for Lp(a) Testing

EP. 10 Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP. 10 Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP. 11 Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP. 11 Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP. 12 FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP. 12 FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP. 13 The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP. 13 The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP. 14 Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

EP. 14 Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

EP. 15 Lp(a) Testing: Prevalence and Strategies to Improve Uptake

EP. 15 Lp(a) Testing: Prevalence and Strategies to Improve Uptake

EP. 16 Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

EP. 16 Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

EP. 17 Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

EP. 17 Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

EP. 18 Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

EP. 18 Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

Video content above is prompted by the following:

The NLA’s 2024 recommendation comes as a “focused update” to its 2019 scientific statement on the use of Lp(a) in clinical practice. Should providers wait for another complete scientific statement from NLA—or for new guidelines from AHA or other organizations—before implementing this recommendation?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Amid SOHO Data, Reviewers of BTK Inhibitors in MCL Call for Trials

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare

Counseling Vitiligo Patients on Time to Repigmentation